Handelsbanken Fonder AB Lowers Stake in Gilead Sciences, Inc. $GILD

Handelsbanken Fonder AB lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,151,328 shares of the biopharmaceutical company’s stock after selling 12,992 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.09% of Gilead Sciences worth $127,797,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth $26,000. Putney Financial Group LLC raised its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Howard Hughes Medical Institute bought a new position in Gilead Sciences in the second quarter worth about $30,000. MTM Investment Management LLC lifted its position in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares during the last quarter. Finally, Kilter Group LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on GILD shares. Wolfe Research boosted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Scotiabank upped their price target on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 11th. HSBC increased their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Finally, Leerink Partners boosted their target price on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $156.72.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 299,280 shares of company stock worth $42,487,570 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for $115 per share in cash, a $7.8 billion deal that boosts Gilead’s oncology/cell-therapy exposure and adds potential long‑term growth avenues. The transaction is material in size and supports the company’s pipeline diversification. Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
• Positive Sentiment: New Phase 3 ARTISTRY data showed Gilead’s single‑tablet bictegravir/lenacapavir maintained virological suppression with low discontinuation rates — supportive for Gilead’s long‑acting HIV franchise and potential market share gains on switches. Gilead’s experimental HIV treatment shows low discontinuation rates in studies
• Positive Sentiment: Daiwa raised its price target to $161 and kept an “outperform” rating, implying notable upside versus current levels — a helpful analyst endorsement for sentiment. Daiwa Securities Adjusts Price Target on Gilead Sciences to $161
• Positive Sentiment: Zacks issued a series of upward EPS revisions across 2026–2028 (FY2026 to $8.54, FY2027 and FY2028 also raised) and lifted multiple quarterly estimates, which supports a stronger forward earnings outlook versus consensus. (Zacks research notes)
• Positive Sentiment: UBS reiterated a Buy and maintained a $175 price target, highlighting confidence in Gilead’s long‑acting HIV strategy. Gilead Sciences: Advancing Long-Acting HIV Franchise Underscores Competitive Edge and Supports Buy Rating
• Neutral Sentiment: Kymera Therapeutics reported strong results in its Q4 update — broadly positive for the biotech sector but not directly material to Gilead’s immediate fundamentals. Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights
• Negative Sentiment: Merck’s two‑drug HIV regimen matched Gilead’s Biktarvy in Phase 3 and is under FDA review — this increases competitive pressure in the core HIV market and could weigh on future market share/pricing. Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
• Negative Sentiment: Zacks trimmed its Q3 2026 EPS estimate slightly (from $2.34 to $2.30), a modest near-term downtick in expectations that may contribute to selling pressure. (Zacks research note)

Gilead Sciences Trading Down 2.3%

NASDAQ:GILD opened at $143.77 on Friday. The company has a market capitalization of $178.48 billion, a P/E ratio of 21.24, a PEG ratio of 1.93 and a beta of 0.36. The company has a current ratio of 1.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The firm has a fifty day simple moving average of $135.61 and a 200-day simple moving average of $124.58.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the business posted $1.90 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is currently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.